HEPATOCELLULCAR CARCINOMA
Clinical trials for HEPATOCELLULCAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEPATOCELLULCAR CARCINOMA trials appear
Sign up with your email to follow new studies for HEPATOCELLULCAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for liver cancer: drug combo targets tumors after immunotherapy fails
Disease control Recruiting nowThis phase 2 trial tests whether combining dalpiciclib (a CDK4/6 inhibitor) with camrelizumab (an immunotherapy) can shrink tumors in 30 people with advanced liver cancer that progressed after prior immunotherapy. The study aims to find a new second-line option for this hard-to-t…
Matched conditions: HEPATOCELLULCAR CARCINOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 22:18 UTC
-
New hope for liver cancer: study tests two drug combos after first treatment fails
Disease control Recruiting nowThis study is for people with advanced liver cancer whose first treatment (bevacizumab plus sintilimab) stopped working. It compares two second-line approaches: adding lenvatinib to the original regimen or switching to regorafenib plus a PD-1 inhibitor. The goal is to see which c…
Matched conditions: HEPATOCELLULCAR CARCINOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 18, 2026 11:48 UTC